Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe page revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no changes to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the Study Details page.SummaryDifference0.1%

- Check76 days agoChange DetectedMinor UI and labeling updates were made to the page, including the glossary toggle labels (Show glossary / Hide glossary) and new text such as "Last Update Submitted that Met QC Criteria", "No FEAR Act Data", and "Revision: v3.4.0", while the older phrasing "Last Update Submitted that met QC Criteria", "No FEAR Act data", and "Revision: v3.3.4" were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check83 days agoChange DetectedThe page shows a minor revision history update: added Revision: v3.3.4 and removed Revision: v3.3.3. This change does not affect study details or user actions; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.